Remiges Ventures Inc
05/27/2021 | Press release | Archived content
The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
News
News The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
05/27/2021
We are pleased to announce that the scientific discovery which forms the platform technology for Imel BioTherapeutics, one of our portfolio companies, was published in Scientific Reports on May 25th, 2021.
The discovery is about generation of somatic mitochondrial DNA replaced cells by the team at Kyoto Prefectural University of Medicine, led by Prof. Satoshi Gojo, the scientific founder of Imel BioTherapeutics, Inc.
The discovery is protected by patents globally and provides the firm's core platform technology to develop cell based therapy to treat diseases associated with inherited and acquired mtDNA mutations.
Remiges Ventures Inc published this content on May 27, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2026 at 06:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]